REG - Immupharma PLC - Financial, Business and Portfolio Develop't Update

ImmuPharmaAnnouncement

06/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240306:nRSF7235Fa&default-theme=true

RNS Number : 7235F  Immupharma PLC  06 March 2024

 

RNS 06 March 2024

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Financial, Business and Portfolio Development Update

 

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development
company, is pleased to announce a positive and comprehensive financial,
business and portfolio development update.

 

This follows on from our announcement on 19 December 2023, where we provided a
detailed update on our late stage P140 (Lupuzor™) program, in patients with
systemic lupus erythematosus ("SLE/Lupus").

 

Financial Overview

ImmuPharma would firstly like to confirm that the financing position of the
Company is sufficient for its immediate requirements and it has no current
plans to raise equity through the capital markets.

Future cash requirements are fully expected to be met through non-dilutive
income derived from the Company's portfolio of assets including, inter alia,
new commercial deals on the development portfolio, including the non-US rights
for P140 (SLE/Lupus); the worldwide rights for CIDP and for BioAMB. The
Company is in active discussions with a broad range of potential commercial
partners with the objective of completing deals across the portfolio in 2024.

To put this all into perspective, since the reorganisation of the Company,
which was initiated in August 2021, the Board of Directors has greatly
simplified the Group corporate structure; reduced staff levels; eliminated
unnecessary and expensive overhead costs and most importantly, focused the
development portfolio into two areas; Autoimmune and Anti-Infectives.

 

ImmuPharma now has two late-stage autoimmune development programs through its
P140 platform, for both SLE and CIDP. Also in the portfolio are two earlier
anti-infective programs, BioAMB and BioCin. Prior to 2021, the portfolio was
primarily focused on only P140 for SLE (Lupus). It is from this enhanced and
improved development portfolio that our shareholders will see the future value
accretion.

 

From an ongoing financial management perspective, we have seen a massive
reduction of more than 75% in the annual overhead cost of the Company,
compared to prior to the reorganisation. Hence, the cash needs of the Company
are significantly less than historically and, as a consequence, much easier to
forecast and manage.

 

We are expecting to announce our audited Full Year Results in May 2024.

 

 

Business Update

Our business model is clear, focused and simple, for the Company to internally
advance its development portfolio up to the point whereby we can enter into
commercial deals with larger companies within the industry that then assume
the responsibility to fund and complete the clinical development of each
product through to registration and ultimately, market launch.

The financial business model underlying this approach provides an optimum
number of opportunities across a range of indications and commercial deals.

In each of these potential deals we would expect to receive significant
up-front payments on signing, with further receipts on achievement of
development and/or sales milestones plus royalties on sales.

The therapeutic indications of our products will be entering markets which
offer the realistic prospect of multi-billion dollar annual sales, which in
turn, will be reflected in the levels of income we expect to be receiving in
both the short, medium and long term.

It is this expectation which will drive the fundamental value of the Company
and deliver the return on investment to our shareholders.

The re-focus and expansion of our portfolio development including the recent
important advances in determining the clinical path through for our late stage
P140 platform and elucidating its unique mechanism of action ("MOA") has
generated significant interest from a wide range of potential commercial
partners.

This commercial interest includes discussions on the non-US rights for P140
("SLE"); the worldwide rights for P140 ("CIDP") and the worldwide rights for
BioAMB.

Whilst there can be no guarantee of completing commercial deals, there are a
broad range of discussions currently taking place and the objective is to
complete deal(s) across the portfolio in 2024.

 

Development Portfolio

P140 | SLE/Lupus Program

 

Further to our update announcement on 19 December 2023 and in collaboration
with Simbec-Orion, the preparatory steps for the new Phase 3 study are
continuing to progress. As we reach key milestones within the study, such as:
site initiations; patient recruitment and patient dosing, we will announce
updates accordingly.

 

As a reminder, the progress update in December included:

 

·    Simbec-Orion appointed as the Contract Research Organisation ("CRO"),
for the P140 (Lupuzor™) Phase 3 study in SLE;

·    Decision to go straight into an international Phase 3 dose-range
study, rather than the longer and more expensive Phase 2/3 adaptive study;

·    Confirmation that the current Phase 3 study is substantially
different from the previous Phase 3 study completed by the Company and
incorporates many changes in the protocol, including significantly higher
doses; and

·    Important further insights into P140's mechanism of action ("MOA")
supporting its position as the only non-immunosuppressing molecule in clinical
development in the industry, creating a 'first-in-class' treatment for many
autoimmune diseases.

 

 

P140 | CIDP Program

 

Progress has also been made in our second late-stage development program, for
chronic idiopathic demyelinating polyneuropathy ("CIDP").

 

We are pleased to announce that Simbec-Orion, has been appointed as the CRO
for this program.

 

In conjunction with Simbec-Orion, an IND application ("INDA") has been
prepared for submission to the FDA, incorporating all their previous guidance
points.

 

In addition, an application for Orphan Drug status for CIDP is being submitted
in parallel to the INDA.

 

As background, in 2023, the Company received positive feedback from the FDA at
a pre-Investigational New Drug meeting, that confirmed that a Phase 2/3
adaptive clinical trial will be the first pivotal stage study of P140 in
patients with CIDP.

 

The FDA feedback recognised that P140 is suitable to be studied in another
disease indication in addition to SLE and this strongly supports the
underlying science and mechanism of action of P140 across several
auto-immune/inflammatory diseases, again a significant breakthrough for the
P140 platform.

 

Anti-Infectives Program | BioAMB | for systemic fungal infections

 

BioAMB is a novel drug that offers a potential improvement on the limiting
side effects and poor administration regime of current Amphotericin-B ("AMB")
formulations. AMB is one of a last line of agents against serious and
life-threatening fungal infections caused by the aspergillus family of fungi.

 

Although AMB is highly effective, currently marketed AMB formulations may
cause serious kidney toxicity and other severe reactions. BioAMB is not a
typical reformulation but a Bio-drug entity, which releases AMB as the active
agent.

BioAMB, is a groundbreaking amphotericin-B variant that promises both
efficiency and safety.

After multiple in vivo studies assessing the Pharmacokinetic/Pharmacodynamic
("PK/PD") and safety profile of BioAMB, the dose-effect relationship has now
been assessed in Part 1 of a new dose-range pharmacodynamic study in an
aspergillosis rat model. Part 1 has now been completed.

 

We are pleased to announce that no toxicity related to BioAMB was observed at
the active dose.

We will now move forward to Part 2 of the study which will further evaluate
the safety of BioAMB at the active dose and confirm the advantage of BioAMB
over the other forms of AMB.

 

It is the intention of ImmuPharma to partner this programme and initial
discussions have commenced.

Incanthera - Financial Asset

In December 2023, ImmuPharma highlighted that Incanthera plc ("Incanthera"),
the dermatology and oncology specialist, had concluded a significant
commercial skincare deal with Marionnaud (part of the A.S. Watson Group)
initially across Europe and with further roll outs across Asia. It confirmed
that this deal is expected to generate significant revenues and profitability
for Incanthera, in 2024 and beyond.

 

Since then, Incanthera's share price has performed strongly.

 

ImmuPharma owns 9.9 million shares in Incanthera, representing a 10.8% holding
with a value of £916k (as at close of business on 05 March). In addition, the
Company also has 7.3 million warrants in Incanthera, which are exercisable at
any time.

 

This represents a significant financial asset for ImmuPharma.

 

With progressive positive news flow expected from Incanthera during 2024, it
would be anticipated this will have a significant positive impact on the value
of the Company's underlying shareholding.

 

 

 

Commenting on the announcement, Tim McCarthy, CEO of ImmuPharma, said:

 

"Since our update in December 2023, ImmuPharma has continued to make positive
progress within our key programs, as highlighted in this statement.

 

Against a backdrop of continued market volatility, that has adversely affected
many small companies' share prices, including our own, the Board believes the
underlying value of our assets continues to be strengthened.

 

ImmuPharma has a unique portfolio, including two late-stage assets that now
have overwhelming evidence to be potential first line treatments in
debilitating auto-immune diseases such as Lupus and CIDP, markets of high
unmet medical need and multi-billion-dollar revenues.

 

It is this profile that has generated so much interest from potential
commercial partners and our focus for 2024 is to secure commercial deals for
these programs.

 

The Board is positive about the short, medium and long-term future for
ImmuPharma and thanks all those shareholders who continue to support the
Company."

 

 

 

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation no 596/2014 which is part of English
law by virtue of the European (withdrawal) Act 2018, as amended.  On
publication of this announcement via a regulatory information service, this
information is considered to be in the public domain.

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                         + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                           +44 (0) 203 368 3550 (about:blank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                          +44 (0) 203 650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                         +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class
autophagy immunomodulator for the treatment of Lupus and preclinical analysis
suggest therapeutic activity for many other autoimmune diseases that share the
same autophagy mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(http://www.immupharma.co.uk)

 

P140 MOA

 

The lack of immunosuppression is explained by our refined MOA. All other
molecules in development demonstrate varying degrees of immunosuppression,
which give rise to side effects and limit the dose that can be used to achieve
efficacy.

 

New evidence shows that P140 restores the tolerance systems by enabling
tolerogenic antigen presenting cells (like dendritic cells) to function
properly. As malfunction of the tolerance systems seems to be the root cause
of most if not all autoimmune diseases, it explains why P140 is so broadly
efficient across most autoimmune indications in animal models. P140 is the
only non-immunosuppressive molecule in the industry in clinical development
for the treatment of SLE.

 

This distinction sets the stage for a new gold standard therapy, conveniently
self-administered by the patient, once a month, which is safe and well
tolerated unlike standard of care or any other molecule in development which
are all immunosuppressants with significant safety warnings.

 

 

 

 

 

 

About Lupus (Systemic Lupus Erythematosus / SLE)

 

Lupus is a chronic inflammatory disease which is thought to affect some 16
million individuals worldwide. The current standard of care still consists of
steroid and anti-malarial therapies which many have side-effects and poor
response in many patients. Recently more targeted monoclonal therapies are
GlaxoSmithKline's Benlysta and more recently, AstraZeneca's Saphnelo. There
still exists a high unmet medical need for a drug that has a strong efficacy
and safety profile.

 

About CIDP (Chronic Idiopathic Demyelinating Polyneuropathy)

 

CIDP is a rare acquired autoimmune disorder of peripheral nerves which is
thought to affect some 90,000 individuals across US/Europe.  It is a rare
neurological disorder characterized by progressive weakness and impaired
sensory function in the legs and arms. CIDP related disability may be
substantial. In addition to the physical burdens imposed by the disease, those
affected by CIDP also frequently experience economic and emotional hardship
and are often burdened not only by the disease but also by the immunotherapies
used to treat the disease. Other than intravenous (IVIG) and subcutaneous
immunoglobulin (SCIG), corticosteroids and plasma exchange are the only other
treatment options. There is still a huge unmet need for more efficacious drugs
that are safer and which affect underlying disease progression.

 

About Simbec-Orion

Simbec-Orion, is an experienced, full-service Contract Research Organisation,
with offices across the UK, Europe, and the United States. Established for
over 45 years, and leveraging deep experience delivering first in human
(https://www.simbecorion.com/service/phase-1/)  clinical trials, providing
bespoke clinical trial services to small to mid-sized biotech and
pharmaceutical partners across Europe, North America and beyond. Across the
organisation scientific teams leverage both a wide therapeutic experience in
clinical pharmacology, such as CNS, respiratory, dermatology, vaccines and
anti-infectives, to more specialist expertise in Phase I-IV rare disease
(https://www.simbecorion.com/service/rare-diseases/)  and oncology
(https://www.simbecorion.com/service/oncology/) .

For more information, visit www.simbecorion.com (http://www.simbecorion.com)

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFFFSFVTIEIIS